How profitable is Abbott Laboratories (ABT)?

In FY 2025 (10-K), ABT converted $44.3B of revenue into a 56.4% gross margin, 18.2% operating margin, and $7.4B in free cash flow (16.7% FCF margin).

Stock Ratings / Health Care / ABT / financials

NVO (58) PFE (74) VRTX (83) BMY (67) ⌘ Pro Terminal →

Abbott Laboratories (ABT) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$110.16 +3.73% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $111.16

Abbott Laboratories (ABT) earns a Roarable Rating of B+ (Buy) with 77/100 RQD Confidence. High-quality cash engine (56.4% gross margin, 12% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B+ • BUY Cap $183.77B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ABT Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ABT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Abbott Laboratories (NYSE: ABT) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 77/100 at a spot price of $110.16 (+3.73% 1D, market cap $183.77B). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 15/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 16/20, and Executive Insider Alignment 14/20. Across 1015 tracked Health Care issuers, ABT ranks #23 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ABT compare to NVO and PFE in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ABT carries a Roarable B+ (77/100 RQD), trailing P/E of 27.7x, gross margin of 56.4%, and ROIC of 11.9%. By comparison, NVO (Novo Nordisk A/S) holds a D+ grade (58/100 RQD, P/E 32.8x, ROIC 9.9%, cap $177.12B) and PFE (Pfizer Inc.) posts a B grade (74/100 RQD, P/E 22.0x, ROIC 5.1%, cap $173.95B). Among the 5-stock peer group, BMY leads on earnings multiple (17.8x) while VRTX leads on capital efficiency (20.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ABT?

▼

Per ABT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000001800), Abbott Laboratories generated $44.33B in revenue (+5.7% YoY), $6.52B in net income, and $7.39B in free cash flow against $86.71B in total assets and $9.90B in total debt. Key quantitative strengths: Strong cash generator (56.4% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $111.16 (+0.91%)🧬 Cannibal Buyback (-1.80% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 16.7% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 77/100 (B+) historically ranked in the Top 10% of excess returns over the next 90 days (+7.8% avg 90D alpha vs SPY • 70.3% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERBUY • B+

3-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B · Rk B+

Each axis scored 0–20

12M PRICE TARGET CONE+8.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ABT)Realized 20D OHLCV Swing Band: ±5.5%

Deterministic 5-Pillar Attribution (77/100 Composite)

🔍 WHY ABT SCORES 77/100 (B+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+16/20 pts (21% of score)

SEC XBRL FY 2025 (10-K): 16.7% FCF Margin ($7.39B FCF) & 56.4% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (21% of score)

Altman Z-Score 4.36 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution14/20 pts (-6 pt drag)

Cannibal Buyback (-1.80% YoY Shares) & executive Form 4 sales trim 6 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B-$102.97-2.4% Next Q

Q2 (-2Q)

Grade B$100.51+2.1% Next Q

Q3 (-1Q)

Grade B+$102.64+7.3% Next Q

Current

Grade B+$110.16+7.8% Hist 90D α

Trajectory: B- (69) → B+ (77)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the ABT Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 77/100 (B+) score, ABT faces multiple-compression risk if 27.7x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.80% YoY Shares) — any gross margin slip below 53.9% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($103.66) or 200D SMA ($101.44) invalidates the momentum regime and cuts Target Base ($119.58) toward Bear Floor ($90.33).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ABT• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ABT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 77%NO 23%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How ABT Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$7.39B (16.7% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $40.11B

FY24

Rev $41.95B

FY25

Rev $44.33B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$44.33B	56.4%	18.2%	$6.52B	$7.39B	11.9%
FY 2024	$41.95B	55.4%	16.3%	$13.40B	$6.35B	10.2%
FY 2023	$40.11B	56.4%	16.2%	$5.72B	$5.46B	8.5%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ABT)

✓Walkthrough of ABT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ABT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +25.84%▲ RESISTANCE BREAKOUT

2026-11-03O $104.6H $110.2L $104.6C $110.2VOL 8.44M

RES: $105.7SUP: $98.07SMA50: $103.7SMA200: $101.4

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ABT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ABT Butterfly Map → + Track ABT →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

21.2%/yr Implied 5Y Growth

vs. +5.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ABT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ABT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ABT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ABT)

Health Care Rank #23 of 1015 ⚔️ NVO vs ABT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ABT vs. NVO, PFE, VRTX, BMY)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Abbott Laboratories (ABT) ranks #23 by composite RQD confidence (77/100, grade B+) and #11 by equity capitalization ($183.77B). Within this direct 5-issuer industry benchmark cohort, BMY leads on earnings valuation at 17.8x trailing P/E, while VRTX leads on capital efficiency and profitability with 20.0% ROIC and 86.2% gross margin. VRTX currently holds the highest overall quantitative score in the immediate peer group at 83/100 (A-) compared with ABT at 77/100 (B+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ABT ACTIVE Abbott Laboratories	B+	77/100	27.7x	56.4%	11.9%	+3.73%	$183.77B	Benchmark Subject
NVO Novo Nordisk A/S	D+	58/100	32.8x	—	9.9%	+1.13%	$177.12B	/nvo-vs-abt →
PFE Pfizer Inc.	B	74/100	22.0x	74.3%	5.1%	+0.49%	$173.95B	/pfe-vs-abt →
VRTX Vertex Pharmaceuticals Incorporated	A-	83/100	34.6x	86.2%	20.0%	-1.02%	$141.65B	/vrtx-vs-abt →
BMY Bristol-Myers Squibb Company	C+	67/100	17.8x	71.1%	13.3%	+0.86%	$127.71B	/bmy-vs-abt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000001800 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Abbott Laboratories (ABT) reported GAAP revenue of $44.33B (+5.7% vs. FY2024 revenue of $41.95B , and +10.5% cumulative change since FY2023) , GAAP net income of $6.52B, operating cash flow of $9.57B, and free cash flow of $7.39B (+16.4% YoY). On the balance sheet, ABT closed FY2025 with $86.71B in total assets against $9.90B in total debt (Altman Z-Score: 4.36, Piotroski F-Score: 8/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$44.33B	$6.52B	$9.57B	$7.39B	$86.71B	$9.90B
FY2024 (FY)	2024-12-31	$41.95B	$13.40B	$8.56B	$6.35B	$81.41B	$12.63B
FY2023 (FY)	2023-12-31	$40.11B	$5.72B	$7.26B	$5.46B	$99.52B	$23.29B

3. ABT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ABT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ABT compare to NVO and PFE in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ABT?

Where is ABT trading relative to its 50-day, 200-day, and 52-week technical levels?

ABT last traded at $110.16 (+3.73% on volume of 8,846,372 shares), positioning the stock +6.27% above its 50-day simple moving average ($103.66) and +8.60% above its 200-day simple moving average ($101.44). Across its 52-week range of $81.97 to $132.03, ABT sits at the 56.3% percentile with a 14-day RSI of 58.5 (BULLISH MOMENTUM) and an implied next-earnings move of ±5.5% ($104.10 to $116.22).

Direct Sub-Reports: ABT RQD Cockpit ABT 12M Forecast ABT Earnings & Move ABT Dividends & DRIP ABT Insiders & 13F ABT Whale Options ABT Profit Sankey ABT News & Why

ROARABLE RATING BRIEF • RQD 77/100 (B+) ✓ SEC XBRL & RQD VERIFIED

ABT — Abbott Laboratories: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Abbott Laboratories (ABT) earns a live Roarable RQD composite score of 77/100, corresponding to a B+ letter grade (Roarable Buy) at a spot price of $110.16 (+3.73% 1D, market capitalization $183.77B).

Fundamental Cash Engine (16/20): Anchored by return on invested capital (ROIC) of 11.9%, gross margin of 56.4%, operating margin of 18.2%, and free cash flow yield of 4.09%.
Whale 13F & Options Flow (15/20) + Insider Conviction (14/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (16/20) + Forensic Balance Sheet (16/20): Incorporates a 0.99x equity beta, Altman Z-Score of 4.36, Piotroski F-Score of 8/9, and Debt/Equity of 0.19x.

2. Business Model, Unit Margins & SEC Financial Trajectory

. The profile provides no product list, customer base, or revenue-mix detail.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Abbott Laboratories (ABT) reported $44.33B in annual revenue (up from $41.95B in FY2024, +5.7% YoY) and $6.52B in GAAP net income. Over the multi-year SEC filing window from FY2023 ($40.11B revenue, $5.72B net income) through FY2025, ABT scaled operating cash flow to $9.57B and free cash flow to $7.39B, backed by $86.71B in total assets against $9.90B in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (B+ • RQD 77/100): Strong cash generator (56.4% gross margin)—profits are backed by real money, not accounting tricks. Big institutional funds and options desks are actively positioning on the bullish side. With Fundamental Cash Engine at 16/20 and Institutional Whale Flow at 15/20, sustained execution supports upside toward the upper end of the $81.97 – $132.03 52-week range.
🐻 Primary Bear Case & Valuation Risk: Broader market pullbacks can still drag down strong stocks in the short run. Investors must weigh 27.7x trailing P/E and 18.4x EV/EBITDA against 18.2% operating margins and a 0.99x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), ABT carries a macro regime beta of 0.99 and gross margin of 56.4%.

Key Question #1: Can ABT sustain or expand its 18.2% operating margin and 11.9% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $44.33B and free cash flow of $7.39B, how will capital allocation balance growth reinvestment against $9.90B in total debt?
Key Question #3: How sensitive is ABT's 25.8x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.99x)?

ABT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Abbott Laboratories (ABT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ABT Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 22h ago

Abbott (ABT) Stock Could Be 24% Overvalued After Heart Failure News

Yahoo Finance report covering Abbott Laboratories (ABT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ChartMill • 1d ago

Abbott Laboratories (NYSE:ABT): A Quality Stock With Durable Fundamentals

ChartMill report covering Abbott Laboratories (ABT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Trefis • 1d ago

Abbott Laboratories Earnings Ahead: What Past Reactions Say About The Stock

Trefis report covering Abbott Laboratories (ABT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The Motley Fool • 1d ago

History Says Abbott Stock Could More Than Double by 2036. Here’s Why I Just Added It to My Portfolio.

The Motley Fool report covering Abbott Laboratories (ABT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investor's Business Daily • 1d ago

Abbott Yo-Yoes On 'Choppy' Third Quarter As A Key Spinoff Looms

Investor's Business Daily report covering Abbott Laboratories (ABT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingKey • 1d ago

Abbott Laboratories Stock (ABT) Moved Up by 3.08% on Oct 5: Facts Behind the Movement

TradingKey report covering Abbott Laboratories (ABT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Is Most-Watched Stock Abbott Laboratories (ABT) Worth Betting on Now?

Yahoo Finance report covering Abbott Laboratories (ABT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The Motley Fool • 1d ago

Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026?

The Motley Fool report covering Abbott Laboratories (ABT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ABT Bull vs. Bear Conversation Board — What's Your Call at $110.16?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ABT 🐻 33% BEARISH CONVICTION

MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $124.25 (+17.0%)

📌 Pinned Debate

Strong balance sheet (Altman Z 4.36, Piotroski F 8/9, Debt/Equity 0.19) and an 11.9% ROIC support a Roarable Buy rating of 77/100.

The street is overcomplicating Abbott Laboratories (ABT). Strong balance sheet (Altman Z 4.36, Piotroski F 8/9, Debt/Equity 0.19) and an 11.9% ROIC support a Roarable Buy rating of 77/100.. With an RQD score of 77/100 (B+) and Forensic Balance Sheet at 16/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $114.70.

CapAlloc_Nerd 🐂 BULL

@MidwestValue Agree on the RQD 77/100 quality, though with 0.99 beta I'm scaling in with half-size at $106.20 and keeping dry powder in case we test $98.77.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $79.65 (-25.0%)

Spot @ $106.20

A trailing P/E of 27.7 and EV/EBITDA of 18.4 leave valuation exposed if earnings growth slows.

I respect the product at Abbott Laboratories, but the stock at $106.20 is a different story. A trailing P/E of 27.7 and EV/EBITDA of 18.4 leave valuation exposed if earnings growth slows.. FCF yield is 4.09% and RQD sits at 77/100 (B+) — why pay up here when you can wait for next quarter's numbers?